Catch Bio, a U.S.-based preventive healthcare startup using artificial intelligence and biomarker-driven analytics to assess long-term cancer risk, has raised seed funding as it scales its personalized cancer risk prediction platform and expands clinical validation of its preventative health model.

The company builds an AI-powered system that evaluates hundreds of biological, genetic, and lifestyle risk factors to estimate an individual’s probability of developing major cancer types over time. Its platform integrates biomarker testing with machine learning models to continuously update personalized risk scores and generate prevention-oriented health plans aimed at early intervention and long-term risk reduction. The system is designed to shift healthcare from reactive diagnosis to proactive prevention by identifying risk patterns years before disease onset.

Catch Bio’s platform analyzes more than 500 risk variables, combining clinical lab data with longitudinal health inputs to produce individualized cancer risk assessments. Users receive structured screening recommendations, lifestyle guidance, and periodic updates as new biomarker data becomes available, enabling an evolving preventive care model rather than static health reporting.

The company has raised approximately $750,000 in a seed round, according to disclosed funding filings, marking its first formal institutional financing event. The capital is being used to expand its AI-driven risk engine, strengthen clinical validation efforts, and scale its consumer subscription model, which provides ongoing cancer risk tracking and preventive care recommendations.

The seed round includes participation from Hannah Grey VC, a venture capital firm focused on early-stage investments in AI, healthcare, and consumer technology. The firm typically backs startups building personalized, data-driven systems that reshape user behavior and long-term health outcomes.

Investors in the round include Hannah Grey VC, which invests in early-stage companies focused on transforming healthcare and consumer experiences through data and artificial intelligence.

Catch Bio operates within the rapidly growing preventive health and precision diagnostics sector, where startups are increasingly leveraging AI to identify disease risk before clinical symptoms appear. Unlike traditional diagnostic companies that focus on detecting existing illness, Catch Bio emphasizes predictive modeling and continuous risk assessment based on evolving biological data.

The company’s subscription-based model provides users with annual biomarker testing, personalized cancer screening schedules, and dynamically updated risk mitigation strategies. This system is designed to create a feedback loop between clinical data and predictive analytics, allowing users to adapt health behaviors in response to changing risk profiles over time.

Catch Bio’s approach aligns with broader trends in longevity science and preventive medicine, where AI-driven platforms are increasingly used to model disease risk trajectories and guide early interventions. By combining machine learning with clinical biomarkers, the company aims to improve early detection rates and reduce the incidence of late-stage cancer diagnoses.

The funding will support expansion of Catch Bio’s clinical partnerships, enhancement of its AI modeling infrastructure, and scaling of its consumer health platform. The company is also investing in improving data integration across biomarker testing providers and healthcare systems to strengthen the accuracy of its predictive models.

As preventive healthcare continues to gain traction, Catch Bio is positioning itself at the intersection of artificial intelligence, clinical diagnostics, and consumer health technology. With its seed funding and backing from investors such as Hannah Grey VC, the company is advancing its mission to make personalized cancer risk prediction and prevention more accessible and actionable for individuals.

Related Articles